

#14  
7648

59597-D/JPW/AJM/DRM

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Neil T. Parkin and Rainer A. Ziermann  
Serial No. : 09/766,344  
Filed : January 19, 2001  
For : MEANS AND METHODS FOR MONITORING PROTEASE  
INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING  
THERAPEUTIC DECISIONS IN THE TREATMENT OF  
HIV/AIDS

1185 Avenue of the Americas  
New York, New York 10036  
October 9, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

OCT 18 2002

Sir:

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. \$1.56, applicants would like to direct the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (**Exhibit A**). A copy of the disclosures listed below as items 1-3 are attached as **Exhibits 1-3**.

1. U.S. Patent No. 5,837,464 (Capon et al.) issued November 17, 1998;
2. Young, B. et al., Resistance Mutations In Protease And Reverse Transcriptase Genes Of Human Immunodeficiency Virus Type 1 Isolates From Patients With Combination Antiretroviral Therapy Failure, Journal of Infectious Diseases, Vol. 178, No.5, pages 1497-1501 (November 1998); and
3. Hertogs et al., A Rapid Method For Simultaneous Detection Of Phenotypic Resistance To Inhibitors Of Protease And

Applicants : Neil T. Parkin and Rainer A. Ziermann  
Serial No. : 09/766,344  
Filed : January 19, 2001  
Page 2

Reverse Transcriptase In Recombinant Human Immunodeficiency  
Virus Type 1 Isolates from Patients Treated With  
Antiretroviral Drugs, Antimicrobial Agents And  
Chemotherapy, Vol. 42, No. 2, pages 269-276 (February  
1998).

PCT International Application No. PCT/US02/01682, filed January  
8, 2002 is a foreign counterpart application of the subject  
application. A Search Report was issued on July 9, 2002 in  
connection with PCT/US02/01682. A copy of the Search Report is  
attached hereto as **Exhibit B**. The above listed references 1-3  
were cited in the Search Report.

If a telephone interview would be of assistance in advancing  
prosecution of the subject application, applicants' undersigned  
attorneys invite the Examiner to telephone them at the number  
provided below.


^

^

Applicants: Neil T. Parkin and Rainer A. Ziermann  
Serial No.: 09/766,344  
Filed : January 19, 2001  
Page 3


No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231.

  
Alan J. Morrison  
Reg. No. 37,399

10/09/02  
Date

Form PBQ-1449

**U.S. Department of  
Commerce  
Patent and Trademark Office**

**Atty. Docket No.**  
2793/59597-D/JPW/AJM/DRM

**Serial No.**  
09/766,344

**Applicants**  
Neil T. Parkin and Rainer A. Ziermann

<b>Filing Date</b>
January 19, 2001

**Group**  
1648

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	<p>Young, B. et al., Resistance Mutations In Protease And Reverse Transcriptase Genes Of Human Immunodeficiency Virus Type 1</p> <p>Isolates From Patients With Combination Antiretroviral Therapy Failure, <u>Journal Of Infectious Diseases</u>, Vol. 178, No. 5, pages 1497-1501 (November 1998).</p>
	<p>Hertogs et al., A Rapid Method For Simultaneous Detection Of Phenotypic Resistance To Inhibitors Of Protease And Reverse Transcriptase In Recombinant Human Immunodeficiency Drugs, <u>Antimicrobial Agents And Chemotherapy</u>, Vol. 42, No. 2, pages 269-276 (February 1998).</p>

**EXAMINER**

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.